Companies /Healthcare

Abbvie Inc

NYSE: ABBV Drug Manufacturers - General
$256.37
▼ $3.84 (−1.48%) today
Markets closed · 4:34pm ET

Q2 2026 Earnings

Reported Jul 31, 2026, 7:51am ET · SEC source
$3.65
Beat +1.15%
EPS · est. $3.61
$17.0B
Beat +1.40%
Revenue · est. $16.8B
+1.6%
Beating market
ABBV vs S&P since report
1 quarter
Consecutive EPS beats

Market Reaction

% change · around the report
0+2%+4%Jul 31Jul 31report 7:51am ETearnings−0.0%+2.8%
0+2%+4%Jul 31Jul 31earnings−0.0%+2.8%
ABBV +2.8%S&P 500 −0.0%
−2%0+2%+4%Jul 31Jul 31report 7:51am ETearnings−1.0%+2.8%
−2%0+2%+4%Jul 31Jul 31earnings−1.0%+2.8%
ABBV +2.8%NASDAQ −1.0%
0+3%+6%Jul 30Aug 7report 7:51am ETearnings+3.8%−0.1%
0+3%+6%Jul 30Aug 7earnings+3.8%−0.1%
ABBV −0.1%S&P 500 +3.8%
−3%0+3%+6%Jul 30Aug 7report 7:51am ETearnings+4.5%−0.1%
−3%0+3%+6%Jul 30Aug 7earnings+4.5%−0.1%
ABBV −0.1%NASDAQ +4.5%
−2.51%
Day of report
−2.33%
Next session
−1.95%
One week
+3.61%
30 days

S&P 500 over the same 30 days: +1.97%.

Did ABBV Beat Earnings? Q2 2026 Results

AbbVie delivered a solid second quarter in 2026, beating consensus on both the top and bottom lines as its immunology franchise continued to carry the growth story. Adjusted diluted EPS came in at $3.65, clearing the $3.08 consensus estimate by 1.15%, while total net revenues of $16.99 billion topped the $16.76 billion consensus by 1.40% and rose 10.2% year over year. The primary engine behind the outperformance was immunology, where Skyrizi and Rinvoq posted revenue growth of 24.4% and 24.5% respectively, more than absorbing Humira's continued biosimilar erosion to $756 million. Neuroscience added further lift, growing 20.3% to $3.23 billion on the strength of Vraylar and Botox Therapeutic. Looking ahead, AbbVie trimmed its full-year 2026 adjusted EPS guidance range by $0.04 at the midpoint to $13.87 to $14.07, reflecting $0.14 of dilution from its pending $10.90 billion acquisition of Apogee Therapeutics, partially offset by $0.10 of operational overperformance, as the company continues broadening its immunology pipeline ahead of long-term Humira replacement needs.

Key Takeaways
  • Skyrizi net revenues grew 24.4% to $5.505 billion, driven by strong demand across indications
  • Rinvoq net revenues grew 24.5% to $2.525 billion with continued market penetration
  • Neuroscience portfolio grew 20.3% led by Vraylar, Botox Therapeutic, and migraine franchise expansion
  • Vyalev contributed $256 million as a new growth driver in Parkinson's disease
  • Adjusted tax rate declined to 14.7% from 16.2% year over year
  • Acquired IPR&D and milestones expense was $291 million in Q2 2026 vs. $823 million in Q2 2025

“AbbVie delivered another excellent quarter, marked by outstanding execution and pipeline advancement. We also announced the proposed acquisition of Apogee Therapeutics, which strengthens our ability to deliver innovative medicines to patients, bolsters our immunology leadership and creates significant shareholder value.”

AbbVie CEO, on the earnings call

Forward Guidance & Outlook

AbbVie updated its full-year 2026 adjusted diluted EPS guidance range from $13.91–$14.11 to $13.87–$14.07, a reduction of $0.04 at the midpoint. The update reflects $0.14 of dilution from the proposed Apogee Therapeutics acquisition (expected to close in Q3 2026), partially offset by $0.10 of operational overperformance. The guidance includes $0.58 per share of unfavorable acquired IPR&D and milestones expense incurred year-to-date through Q2 2026, and excludes any such expense that may be incurred beyond Q2 as it cannot be reliably forecasted.

ABBV YoY Financials

Q2 2026 vs Q2 2025 · SEC filings Q2 2025 Q2 2026
$0$5.0B$10.0B$15.0B$15.4B$17.0BRevenue$11.1B$12.7BGross Profit$4.9B$6.4BOperating Income$938.0M$3.6BNet Income
$0$5.0B$10.0B$15.0BRevenueGross ProfitOperating IncomeNet Income

ABBV Revenue by Segment

Immunology$8.8B+15.1%
Skyrizi$5.5B+24.4%
Neuroscience$3.2B+20.3%
Rinvoq$2.5B+24.5%
Oncology$1.7B−1.5%
Aesthetics$1.3B+0.3%
Humira$756.0M−35.9%
Vraylar$1.1B+18.9%

ABBV Revenue by Geography

United States$12.9B+9.3%
Rest of World$4.1B+12.8%

Figures from SEC filings and company reports. Not investment advice.